<<< BACK
|
NEWS
Yamanouchi Pharma
America, Inc.
Names Sam Brown Inc.
as Public Relations Agency
Network-based agency provides strategic
communications solutions to support
Yamanouchi’s entry into the
U.S. pharmaceutical market
Newtown Square, PA – July
29, 2002 – Sam Brown Inc. Corporate Communications, announced today that
it has been selected as the public relations agency for Yamanouchi Pharma
America, Inc., the newly formed U.S. subsidiary of Yamanouchi
Pharmaceutical Co., Ltd., the third largest pharmaceutical company in
Japan. Sam Brown Inc. is a corporate communications agency that utilizes a
network of senior consultants to provide highly strategic and cost
efficient communications solutions to the health and science markets, with
an emphasis on the pharmaceutical and biotechnology industries.
Serving on a project basis for the company since January of 2001, Sam
Brown Inc. recently managed the national public relations launch of
Yamanouchi Pharma America into the United States, in addition to the
development of the company’s Web site –
www.yamanouchiamerica.com.
“We chose to partner with Sam Brown because their network model offered us
the ability to work with a team of highly skilled specialists,
knowledgeable in all aspects of corporate communications,” said Stephen
Mader, senior vice president, Yamanouchi Pharma America, Inc. “Whatever
the scope of our needs, Sam Brown can easily access the right resources to
offer the most strategic, creative and effective solutions.”
Moving forward, Sam Brown Inc. will expand its responsibilities to include
product public relations services to support Yamanouchi Pharma America as
they maximize their global product development domestically in the United
States. Yamanouchi currently has a novel compound in development for the
treatment of overactive bladder and is building a urology franchise.
“Given the long-standing success of its parent company, Yamanouchi Pharma
America is positioned to be one of the top pharmaceutical companies in the
United States, and we are pleased to be a part of their growth strategy,”
said Laura M. Liotta, president, Sam Brown Inc.
Sam Brown Inc. is a full-service network agency built on the philosophy
that experienced, senior healthcare communications professionals should
service client accounts. Through its unique structure, Sam Brown accesses
hundreds of professionals in its network tapping into specific strategic
and tactical expertise including public relations, investor relations,
media relations, scientific and consumer writing, research, creative and
Web design. With minimal overhead, dedicated account teams are created
based upon specific client objectives and the strategic and tactical
requirements of the program.
Sam Brown Inc. also serves as the agency of record for GlaxoSmithKline’s
Oncology franchise and brands, including Zofran® (ondansetron HCl),
Hycamtin® (topotecan hydrochloride), Navelbine® (vinorelbine tartrate)
Injection, Argatroban Injection and Bexxar™
(tositumomab, iodine 131 tositumomab), a novel radioimmunotherapy agent in
late-stage development.
About Sam Brown Inc.
Founded in August 1999, Sam Brown Inc. Corporate Communications is a
full-service healthcare agency that utilizes a network of experience
senior professionals to provide specialized expertise, quality strategic
programs and personalized service to the pharmaceutical and biotechnology
industries. For more information on Sam Brown Inc. services or to join the
consultant network, visit
www.sambrown.com.
# # #
Copyright © 1994-2001
meister.NET. All rights reserved.
Legal Notices & Disclaimers
|
